HIT vs CLVT vs VRSK vs HIMS vs MSCI

For growth investors, Health In Tech, Inc.

(HIT) is the stronger pick with 71. 0% revenue growth year-over-year, versus -4. 0% for Clarivate Plc (CLVT). Verisk Analytics, Inc. (VRSK) offers the better valuation at 26. 9x trailing P/E (22. 9x forward), making it the more compelling value choice. Analysts rate MSCI Inc. (MSCI) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Verisk Analytics, Inc.

(VRSK) is the cheapest at 26. 9x versus Health In Tech, Inc. at 78. 5x. On forward P/E, Clarivate Plc is actually cheaper at 3. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: MSCI Inc. wins at 1. 77x versus Verisk Analytics, Inc. 's 2. 68x — a reasonable growth-adjusted valuation.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -90. 0% for Clarivate Plc (CLVT). Over 10 years, the gap is even starker: MSCI returned +720. 9% versus CLVT's -71. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Verisk Analytics, Inc.

(VRSK) is the lower-risk stock at -0. 04β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately -6791% more volatile than VRSK relative to the S&P 500. On balance sheet safety, Health In Tech, Inc. (HIT) carries a lower debt/equity ratio of 1% versus 16% for Verisk Analytics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Health In Tech, Inc.

(HIT) is pulling ahead at 71. 0% versus -4. 0% for Clarivate Plc (CLVT). On earnings-per-share growth, the picture is similar: Clarivate Plc grew EPS 68. 8% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIT leads at 79. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MSCI Inc.

(MSCI) is the more profitable company, earning 38. 4% net margin versus -8. 2% for Clarivate Plc — meaning it keeps 38. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MSCI leads at 54. 7% versus 2. 9% for CLVT. At the gross margin level — before operating expenses — MSCI leads at 82. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, MSCI Inc. (MSCI) is the more undervalued stock at a PEG of 1. 77x versus Verisk Analytics, Inc. 's 2. 68x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Clarivate Plc (CLVT) trades at 3. 8x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 47. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRSK: 32. 4% to $231. 25.

In this comparison, MSCI (1.

2% yield), VRSK (1. 0% yield) pay a dividend. HIT, CLVT, HIMS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Verisk Analytics, Inc.

(VRSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 04), 1. 0% yield, +137. 1% 10Y return). Health In Tech, Inc. (HIT) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRSK: +137. 1%, HIT: -69. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (HIT (Technology) and CLVT (Technology) and VRSK (Industrials) and HIMS (Healthcare) and MSCI (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: HIT is a small-cap high-growth stock; CLVT is a small-cap quality compounder stock; VRSK is a mid-cap quality compounder stock; HIMS is a small-cap high-growth stock; MSCI is a mid-cap quality compounder stock. VRSK, MSCI pay a dividend while HIT, CLVT, HIMS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.